

To: AmeriHealth Caritas New Hampshire Providers

Date: May 12, 2022

Subject: Removal of prior authorization for Sublocade® (buprenorphine extended-release)

injection

Summary: Effective May 2, 2022, Sublocade® (buprenorphine extended-release) injection will no longer require prior authorization.

AmeriHealth Caritas New Hampshire would like to remove barriers for members in need of substance abuse disorder (SUD) treatment. Effective May 2, 2022, we are removing the prior authorization requirement for Sublocade (buprenorphine extended release injection) for both medical and pharmacy claims. A quantity limit, based on FDA dosing of one syringe per 28 days, will remain in place.

On March 28, 2022, we sent a formulary update that indicated that Sublocade® (buprenorphine extended-release) injection would soon require prior authorization. You may now disregard that notice.

Questions:

If you have questions about this communication, please contact AmeriHealth Caritas New Hampshire Provider Pharmacy Services at **1-888-765-6394 (TTY 1-855-809-9206).**

ACNH_221986727